Navigation Links
MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Date:11/26/2007

GAITHERSBURG, Md., Nov. 26 /PRNewswire/ -- MedImmune, Inc. today announced that dosing of patients has begun in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with rheumatoid arthritis (RA), and represents the first clinical trial in which a MAb targeting GM-CSFR is being investigated in this population. MedImmune currently holds exclusive, worldwide rights to develop and market CAM-3001 under an agreement with CSL Limited.

"Commencing this trial demonstrates that researchers at MedImmune are at the forefront of innovation using monoclonal antibodies and evaluating their potential to serve as new treatment options for patients with chronic, debilitating inflammatory diseases, including rheumatoid arthritis," said Ian Anderson, Ph.D., vice president of research -- respiratory, inflammation and autoimmunity.

In MedImmune's Phase 1, dose-escalation trial, patients will receive CAM- 3001 at Charite Research Organisation in Berlin, Germany across a range of escalating doses and will be monitored for up to seven months. Dose escalation will stop if maximum tolerated doses are reached.

CAM-3001, which was isolated and optimized at MedImmune's Cambridge, UK facility using its innovative display platform, inhibits GM-CSF signaling, which has the potential for a significant anti-inflammatory effect. There is substantial evidence for a role of GM-CSF in RA. In preclinical studies, CAM- 3001 has demonstrated potent inhibition of GM-CSF mediated effects in a range of in-vitro and in-vivo assays relevant to RA. Additionally, elevated levels of GM-CSF and its receptor have been found in the joints of patients with RA. This provides a strong rationale for the potential use of CAM-3001 to treat this debilitating disease.

About MedImmune's Anti-GM-CSFR Antibody Development Program

In 2001, MedImmune's Cambridge facility (then known as Cambridge Antibody Technology) and AMRAD Operations Pty Ltd., now owned by CSL Limited, entered into a collaboration to jointly discover and develop human MAb therapeutics that neutralize the GM-CSF receptor, including CAM-3001. Under the terms of a subsequent licensing agreement entered into in August 2007, CSL will receive upfront and milestone payments, as well as royalties, on future sales of CAM- 3001. Additional terms of the agreement have not been disclosed.

About Rheumatoid Arthritis

Rheumatoid arthritis is a chronic systemic inflammatory disease that is associated with significant morbidity and mortality. The disease is characterized by inflammation of the synovial joints that can result in pain, swelling and joint damage with secondary deformity and progressive disability. Despite current treatment options, there is a significant mortality associated with RA, especially the more severe forms of the disease. There is need for additional treatments to control moderate to severely active disease. A new treatment is needed that may provide a significant clinical benefit for disease remission, as well as inhibiting progressive joint damage, and improving quality of life in patients with RA.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):